Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Can-Fite BioPharma Ltd.
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results
Sponsored
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
Sponsored
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
Sponsored
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
Sponsored
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
Sponsored
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
Sponsored
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Sponsored
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
Sponsored
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Sponsored
A New Oral Therapy for Psoriasis Could Be Coming Soon
Sponsored
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
Sponsored
Read More...
Can-Fite BioPharma Ltd. Recent News
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
Sponsored
Dawson James - Can-Fite (CANF) Buy Rated - Expected Milestones
Can-Fite in a letter to shareholders outlined the milestones ahead for the year. Click here for the full report COMFORT-Plaque Psoriasis: Topline Phase 3 Psoriasis Data Expected Q122
Sponsored
CAN-FITE ISSUES LETTER TO SHAREHOLDERS
Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer
Sponsored
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
Namodenoson Headed into Pivotal Phase III Liver Cancer Study
Sponsored
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Earnings Roundup: iAnthus, Can-Fite, Organigram, Bluma Wellness, Auxly
iAnthus Touts 82% YoY Revenue Growth, Names Interim COO